ES2093100T3 - Clones de adnc de celulas t de linfoma. - Google Patents

Clones de adnc de celulas t de linfoma.

Info

Publication number
ES2093100T3
ES2093100T3 ES91908417T ES91908417T ES2093100T3 ES 2093100 T3 ES2093100 T3 ES 2093100T3 ES 91908417 T ES91908417 T ES 91908417T ES 91908417 T ES91908417 T ES 91908417T ES 2093100 T3 ES2093100 T3 ES 2093100T3
Authority
ES
Spain
Prior art keywords
novel
expressed
proteins
cell
dna sequences
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91908417T
Other languages
English (en)
Inventor
Carol L Macleod
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Development Foundation
Original Assignee
Research Development Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Development Foundation filed Critical Research Development Foundation
Application granted granted Critical
Publication of ES2093100T3 publication Critical patent/ES2093100T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Compounds Of Unknown Constitution (AREA)

Abstract

LA PRESENTE INVENCION SUMINISTRA SECUENCIAS NUEVAS DE ADN, MOLECULAS DE ADN RECOMBINANTE (ADNR), PROCESOS PARA PRODUCIR LAS PROTEINAS NUEVAS DE CELULAS T EXPRESADAS EN EL DESARROLLO DE LAS CELULAS T, PROTEINAS NUEVAS DE CELULAS T EN FORMA SUBSTANCIALMENTE PURA Y ANTICUERPOS QUE SE LIGAN A LAS PROTEINAS NUEVAS. MAS PARTICULARMENTE, ESTA RELACIONADA CON SECUENCIAS NUEVAS DE ADN EXPRESADAS EN UN HUESPED ADECUADO Y LAS PROTEINAS NUEVAS DE CELULAS T PRODUCIDAS EN ESTOS HUESPEDES. LA PRESENTE INVENCION TAMBIEN SUMINISTRA PROTEINAS NUEVAS TRANSMEMBRANA EN FORMA SUBSTANCIALMENTE PURA, MOLECULAS DE ADNR QUE CODIFICAN DICHAS PROTEINAS TRANSMEMBRANA Y PROCESOS PARA PRODUCIR LAS PROTEINAS NUEVAS TRANSMEMBRANA. LAS SECUENCIAS DE ADN Y LAS MOLECULAS DE ADN RECOMBINANTE DE ESTA INVENCION SE CARACTERIZAN EN TANTO QUE SE EXPRESAN MEDIANTE CELULAS T LINFOMATICAS Y TIENEN, AL MENOS, UNA DE LAS SIGUIENTES CARACTERISTICAS: (1) SE EXPRESAN EN CELULAS ACTIVADAS NORMALES DEL BAZO, DEL TIMO O EN TEJIDO LINFOIDE ASOCIADO, (2) SE EXPRESAN EN TEJIDO OVARICO, EN EL HIGADO NORMAL Y/O DE FORMA ESPECIFICA RESPECTO A LAS FASES DEL DESARROLLO EMBRIONARIO Y (3) CODIFICAN PROTEINAS NUEVAS TRANSMEMBRANA QUE TIENEN CAMPOS MULTIPLES DE EXTENSION DE MEMBRANAS.
ES91908417T 1990-04-13 1991-04-12 Clones de adnc de celulas t de linfoma. Expired - Lifetime ES2093100T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US50968490A 1990-04-13 1990-04-13

Publications (1)

Publication Number Publication Date
ES2093100T3 true ES2093100T3 (es) 1996-12-16

Family

ID=24027673

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91908417T Expired - Lifetime ES2093100T3 (es) 1990-04-13 1991-04-12 Clones de adnc de celulas t de linfoma.

Country Status (22)

Country Link
US (2) US5312733A (es)
EP (1) EP0527813B1 (es)
JP (1) JPH05506989A (es)
KR (1) KR100212371B1 (es)
AT (1) ATE141105T1 (es)
AU (1) AU664535B2 (es)
CA (1) CA2080018C (es)
DE (1) DE69121240T2 (es)
DK (1) DK0527813T3 (es)
ES (1) ES2093100T3 (es)
FI (1) FI108037B (es)
GR (1) GR3021478T3 (es)
HK (1) HK1006726A1 (es)
IE (1) IE75903B1 (es)
IL (1) IL97775A (es)
NO (1) NO307341B1 (es)
NZ (1) NZ237669A (es)
PT (1) PT97355B (es)
RU (1) RU2116346C1 (es)
SA (1) SA92120348B1 (es)
WO (1) WO1991016430A1 (es)
ZA (1) ZA912489B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6784163B1 (en) * 1990-04-13 2004-08-31 Macleod Carol L. Inhibition of cationic amino acid transporter protein and uses thereof
WO1994004567A1 (en) * 1992-08-21 1994-03-03 La Jolla Cancer Research Foundation A matrix-associating dna-protein, nucleic acids encoding the same and methods for detecting the nucleic acids
US5674704A (en) * 1993-05-07 1997-10-07 Immunex Corporation Cytokine designated 4-IBB ligand
US7211259B1 (en) 1993-05-07 2007-05-01 Immunex Corporation 4-1BB polypeptides and DNA encoding 4-1BB polypeptides
US7138500B1 (en) 1993-05-07 2006-11-21 Immunex Corporation Antibodies to human 4-1BB
US5866329A (en) * 1995-09-27 1999-02-02 Demetriou; Achilles A. Method and probe for detection of gene associated with liver neoplastic disease
US5861248A (en) * 1996-03-29 1999-01-19 Urocor, Inc. Biomarkers for detection of prostate cancer
US6627199B1 (en) * 1999-07-09 2003-09-30 Amgen Inc Isolation, identification and characterization of tmst2, a novel member of the TNF-receptor supergene family
US20030096355A1 (en) * 1999-07-09 2003-05-22 Ke Zhang Isolation, identification and characterization of ymkz5, a novel member of the TNF-receptor supergene family
AU6517800A (en) * 1999-08-04 2001-03-05 Amgen, Inc. Ntr3, a member of the tnf-receptor supergene family
AU783682B2 (en) * 1999-08-04 2005-11-24 Amgen, Inc. Fhm, a novel member of the TNF ligand supergene family
WO2003027276A2 (en) * 2001-09-24 2003-04-03 University Of Aarhus Novel compositions and methods for diagnosis and treatment of lymphoma and leukemia
US20100021953A1 (en) * 2005-08-03 2010-01-28 Astrazeneca Ab Method for Identifying an Agent that Modulates Arginine Transport in a Chondrocyte
US9018004B2 (en) * 2005-11-18 2015-04-28 University Health Network Method of expanding double negative T cells
WO2010141990A1 (en) 2009-06-10 2010-12-16 Stephen Sanig Research Institute Ltd. Methods of generating cells exhibiting phenotypic plasticity

Also Published As

Publication number Publication date
KR100212371B1 (ko) 1999-08-02
EP0527813A1 (en) 1993-02-24
PT97355B (pt) 1998-08-31
EP0527813B1 (en) 1996-08-07
KR930700657A (ko) 1993-03-15
NO307341B1 (no) 2000-03-20
WO1991016430A1 (en) 1991-10-31
CA2080018C (en) 2003-10-14
HK1006726A1 (en) 1999-03-12
FI108037B (fi) 2001-11-15
CA2080018A1 (en) 1991-10-14
NO923918D0 (no) 1992-10-08
FI924575A0 (fi) 1992-10-09
IL97775A (en) 1998-04-05
IE75903B1 (en) 1997-10-08
GR3021478T3 (en) 1997-01-31
IL97775A0 (en) 1992-06-21
RU2116346C1 (ru) 1998-07-27
PT97355A (pt) 1991-12-31
DK0527813T3 (da) 1996-12-30
ZA912489B (en) 1992-01-29
DE69121240T2 (de) 1997-01-09
ATE141105T1 (de) 1996-08-15
JPH05506989A (ja) 1993-10-14
FI924575A (fi) 1992-10-09
SA92120348B1 (ar) 2004-01-24
NZ237669A (en) 1992-08-26
AU7745791A (en) 1991-11-11
EP0527813A4 (en) 1993-05-05
AU664535B2 (en) 1995-11-23
US5312733A (en) 1994-05-17
IE911250A1 (en) 1991-10-23
NO923918L (no) 1992-12-01
US5440017A (en) 1995-08-08
DE69121240D1 (de) 1996-09-12

Similar Documents

Publication Publication Date Title
ES2093100T3 (es) Clones de adnc de celulas t de linfoma.
DE69535375D1 (de) Lösliche polypeptidfraktionen des lag-3-proteins; verfahren zur herstellung; therapeutische zusamensetzung; antiidiotypischer antikörper
NZ323795A (en) Isolated nucleic acid molecules encoding AUR-1 (aurora-1) and AUR-2 polypeptides
EP0590071A4 (en) Substantially pure receptor like tgf--g(b)1 binding molecules and uses thereof
DE69427997T2 (de) Hybrider mensch/tier faktor viii
ATE135371T1 (de) Mit akuter pankreatitis assoziiertes protein, mittel zur diagnose von akuter pankreatitis
IL123189A0 (en) Colon cell and colon cancer cell associated nucleic acid molecules protein and peptides
FI963779A0 (fi) MAGE-kasvainhyljintäantigeeniprekursoreista saatuja eristettyjä peptidejä, jotka kompleksoituvat HLA-A2-molekyylien kanssa
ATE171212T1 (de) Corticotropin freisetzende rezeptoren des faktor 2
ATE247164T1 (de) Insulinartigen wachstumsfaktor bindendes protein
ATE190491T1 (de) Peptide als diagnose- und therapiemittel für spondyloarthropathien
ATE212056T1 (de) Methoden zur herstellung von rna viren aus cdna
ATE281519T1 (de) Klonierung und rekombinante herstellung des crf- rezeptors (crf=corticotropin ausloese faktor)
IL121115A0 (en) C. trachomatis specific peptides and their use in diagnostic assays
MacLeod T-cell lymphoma CDNA clones
AR041564A1 (es) Genes aislados de proteinas de membrana de mamiferos reactivos relacionados
WO2024086741A3 (en) Cd71 binding fibronectin type iii domains
Husain et al. Isolation, molecular cloning and in vitro expression of rhesus monkey (Macaca mulatta) prominin‐1. s1 complementary DNA encoding a potential hematopoietic stem cell antigen
ATE440110T1 (de) Zusammensetzungen und verfahren zur behandlung der polyzystischen nierenkrankheit
Zhang et al. Primary structure of myohemerythrin from Phascolopsis gouldii
Burdge Biochemical analysis of proteolytic fragments from desmosomal glycoproteins.
EP2075335A3 (en) Methods and compositions for inhibiting neoplastic cell growth
RU97106012A (ru) Новые связывающие рка белки и их использование

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 527813

Country of ref document: ES